CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-23). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1474 · Search date 2026-07-23 · Methodology v0.6

One-time abdominal aortic aneurysm ultrasound screening in men aged 65 to 74 years,
does it really help with Reduced abdominal aortic aneurysm rupture and related mortality in older men?

30-Second Summary
A
Evidence Grade A · 90 · Safety unknown
Reductions in AAA rupture and related mortality in men aged 65 to 74 years have been reproduced in several randomized trials
What the
research shows
One-time abdominal aortic aneurysm ultrasound screening in men aged 65 to 74 years is rated A because it reduces AAA rupture and AAA-related mortality. The 2019 USPSTF evidence review pooled long-term data from independent randomized trials including MASS, Viborg, Chichester, and Western Australia and found OR 0.65 for AAA-related mortality, OR 0.62 for rupture, and OR 0.57 for emergency surgery. All-cause mortality showed no significant benefit, with RR 0.99, but disease-specific mortality is the standard hard endpoint for screening. Replication across independent randomized trials gives A with 90 points; evidence in women is insufficient.
What the
ads claim
Promotion may expand a simple ultrasound into lower all-cause mortality for every older adult. Strong evidence primarily concerns AAA-related death and rupture in men aged 65 years or older; the same conclusion does not apply to women or all-cause mortality.
*

Useful facts when choosing a product

  • Abdominal aortic ultrasound is a noninvasive imaging test without ionizing radiation and is generally offered once; direct test harms are minimal.
  • If an aneurysm is found, its size determines whether serial ultrasound surveillance or vascular-surgery assessment is needed.
  • Screening can reduce emergency surgery while increasing elective surgery and total procedures; repair carries cardiovascular complication and mortality risks.
  • Evidence applies mainly to men aged 65 to 74 years, with smoking history, family history, surgical fitness, and life expectancy considered.
Gap Measurement · Verdict 1474 · A 90
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

MASS randomized 67,800 British men aged 65 to 74 years to ultrasound invitation or control and reduced AAA-related mortality. The Viborg trial in 12,639 men aged 65 years or older pointed in the same direction, with Chichester and Western Australia adding independent evidence. The 2019 USPSTF review estimated OR 0.65 for AAA-related mortality and OR 0.62 for rupture across four trials and 124,926 participants followed 12 to 15 years. All-cause mortality was not significantly reduced at RR 0.99, and total procedures increased in screened groups.

02

Why this is classified as A (90)

Long-term meta-analysis of four independent population randomized trials reproduced disease-specific hard-endpoint benefits: OR 0.65 for AAA-related mortality, OR 0.62 for rupture, and OR 0.57 for emergency surgery. All-cause mortality was nonsignificant, but the standard screening endpoint gives A with 90 points.

Counterpoint. The examination itself is low risk, but a positive result leads to long-term surveillance or a repair decision. If a person would not undergo repair or has severe comorbidity that makes repair unlikely to help, the net screening benefit may be smaller.

Rejudgment record. New verdict — Assessed replicated reductions in AAA-related mortality, rupture, and emergency surgery in long-term meta-analysis of the MASS, Viborg, Chichester, and Western Australia population randomized trials, while separating all-cause from disease-specific mortality and evidence in men from that in women

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduction in abdominal aortic aneurysm ruptureALong-term meta-analysis of four randomized trials directly reproduced the benefit with OR 0.62.
Reduction in abdominal-aortic-aneurysm-related mortalityAFour randomized trials and 124,926 participants reproduced a disease-specific mortality benefit with OR 0.65.
Reduction in emergency abdominal aortic aneurysm surgeryALong-term analysis of five trials found OR 0.57, although elective and total procedures increase.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Ashton HA et al. MASS. 2002Multicenter population-based randomized controlled trial67,800United Kingdom Medical Research Council and Department of HealthAAA-related mortality and surgeryInvitation to ultrasound screening significantly reduced AAA-related mortality.Largest key independent randomized trial
Lindholt JS et al. Viborg. 2005Single-region population-based randomized controlled trial12,639Danish public and academic supportAAA-specific and all-cause mortality, elective and emergency surgeryShowed reductions in AAA-specific mortality and emergency surgery.Independent replication
Guirguis-Blake JM et al. USPSTF evidence review. 2019Systematic evidence review and randomized-trial meta-analysis175,085AHRQ and USPSTFAAA death, rupture, emergency surgery, all-cause mortality, and harmsAAA death OR 0.65, rupture OR 0.62, emergency surgery OR 0.57; all-cause mortality RR 0.99.Decisive long-term synthesis
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-23).

Ashton HA, Buxton MJ, Day NE, et al.; Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet. 2002;360(9345):1531-1539. PMID: 12443589. DOI: 10.1016/S0140-6736(02)11522-4.
checked
Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening for abdominal aortic aneurysms: single centre randomised controlled trial. BMJ. 2005;330(7494):750. PMID: 15757960. DOI: 10.1136/bmj.38369.620162.82.
checked
Guirguis-Blake JM, Beil TL, Senger CA, Coppola EL. Primary Care Screening for Abdominal Aortic Aneurysm: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019;322(22):2219-2238. PMID: 31821436. DOI: 10.1001/jama.2019.17021.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none

Cite this verdict

One-time abdominal aortic aneurysm ultrasound screening in men aged 65 to 74 years x Reduced abdominal aortic aneurysm rupture and related mortality in older men Evidence Grade A card
[Chamgap] One-time abdominal aortic aneurysm ultrasound screening in men aged 65 to 74 years x Reduced abdominal aortic aneurysm rupture and related mortality in older men — Evidence Grade A·90. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/one-time-abdominal-aortic-aneurysm-ultrasound-screening-men-65-74/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.